Overview

Update
Total Equity Funding
$20M in 1 Round from 6 Investors
Most Recent Funding
$20M Series A on May 16, 2006
Headquarters:
London
Description:
Viron Therapeutics, a clinical-stage biopharmaceutical company, develops viral proteins to treat and prevent human inflammatory disorders.
Categories:
Biopharma, Biotechnology, Clinical Trials
Website:
http://www.vironinc.com

Company Details

Update

Viron Therapeutics is a clinical stage biopharmaceutical company pioneering the development of viral proteins to treat and prevent human inflammatory disorders. Viral proteins represent a revolutionary new class of drugs. By harnessing the evolutionary power of viruses and other pathogens to evade the human body's protective inflammatory response, Viron is able to identify and develop powerful protein therapeutics that have distinct advantages in potency and efficacy over conventional drug therapy. Viron is the first company to successfully advance a viral protein drug into human testing.

Funding Rounds (1) - $20M

Update
DateAmount / RoundValuationLead InvestorInvestors
May, 2006$20M / Series A6

Board Members and Advisors (1)

Update

Offices/Locations (1)

Update
  • Office

    700 Collip Circle, Suite 203

    Ontario

    London, N6G 4X8

    GBR

Images (1)

Update

Add Acquisitions

Add Current Team

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos